Repare Therapeutics (NASDAQ:RPTX - Get Free Report)'s stock had its "market perform" rating reissued by investment analysts at Lifesci Capital in a report issued on Friday,Benzinga reports.
Several other brokerages also recently issued reports on RPTX. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th. Stifel Nicolaus decreased their price target on shares of Repare Therapeutics from $9.00 to $4.00 and set a "buy" rating for the company in a report on Friday.
Read Our Latest Research Report on RPTX
Repare Therapeutics Price Performance
NASDAQ RPTX traded down $2.20 on Friday, hitting $1.77. 4,696,286 shares of the company were exchanged, compared to its average volume of 191,428. Repare Therapeutics has a twelve month low of $1.66 and a twelve month high of $8.49. The company's 50 day moving average price is $3.30 and its 200-day moving average price is $3.35. The firm has a market capitalization of $75.24 million, a P/E ratio of -0.89 and a beta of 0.71.
Institutional Investors Weigh In On Repare Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC increased its stake in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock worth $29,000 after purchasing an additional 7,800 shares during the last quarter. Stifel Financial Corp raised its holdings in Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company's stock valued at $178,000 after buying an additional 13,800 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company's stock worth $83,000 after buying an additional 4,000 shares during the last quarter. Exchange Traded Concepts LLC lifted its position in shares of Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company's stock worth $174,000 after buying an additional 8,809 shares during the last quarter. Finally, Blue Owl Capital Holdings LP boosted its stake in shares of Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company's stock worth $11,129,000 after acquiring an additional 250,000 shares in the last quarter. 85.09% of the stock is owned by hedge funds and other institutional investors.
Repare Therapeutics Company Profile
(
Get Free Report)
Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.
See Also
Before you consider Repare Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repare Therapeutics wasn't on the list.
While Repare Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
